Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/19/2024 | $15.00 → $10.00 | Buy → Hold | Deutsche Bank |
1/3/2024 | $11.00 | Equal Weight | Barclays |
7/6/2023 | Buy → Hold | Argus | |
4/12/2023 | $13.00 | Equal-Weight | Stephens |
2/1/2023 | $17.00 → $18.50 | Overweight → Neutral | Piper Sandler |
12/7/2022 | $26.00 | Hold → Buy | Argus |
11/9/2022 | $22.00 → $23.00 | Neutral → Buy | Goldman |
11/4/2022 | $17.00 | Overweight | Piper Sandler |
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
NEW YORK, Sept. 29, 2025 /PRNewswire/ -- A new in-depth report by The Insight Partners highlights Practice Management Systems market growth, driven by need for operational efficiency & automation. The comprehensive analysis dives deep into market size, emerging trends, profiles key industry players, and uncovers strategic opportunities shaping the industry landscape. With a spotlight on key market segments and applications, the Practice Management Systems report highlights the factors that drive market momentum in the years ahead. Engineered for Growth: Practice Management Systems on Rapid Ascent Practice Management Systems Market Set to Soar with Demand for Healthcare AutomationValued at U
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene
Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously
Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl
Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go
Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan for an additional six months (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire at 5:00PM New York City time on August 20, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to February 20, 2026. In addition, the amendment to the Rights Plan changes the triggering threshold such that the rights would become exercisable only if a person or group acquires bene
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that management plans to provide a business update after the close of regular stock market hours on June 23, 2025. Veradigm management plans to host an investor conference call and webcast the Company's update at 8:00 a.m. Eastern Time on June 24, 2025. Update Call Details Veradigm plans to distribute an announcement promptly after the close of regular stock market hours on Monday, June 23, 2025. The announcement will also be available at Veradigm investor relations website. To listen to the conference call, participants may log onto the Veradigm investor relations website. Participan
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)